Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 868 posts found.

NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis

June 29, 2018
Medical Communications, Sales and Marketing NICE, Ocrevus, Roche, pharma

Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s …

News

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018
Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …

News

NICE backs Sanofi’s new treatment for atopic dermatitis

June 22, 2018
Medical Communications, Sales and Marketing England, NICE, Sanofi, UK, atopic dermatitis, pharma

NICE has published a positive Final Appraisal Determination FAD recommending dupilumab, in combination with topical corticosteroids, for use on the …

News
roche__tree

Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS

June 22, 2018
Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma

Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …

News
rocherooflr

NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer

June 15, 2018
Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma

Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …

News

NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer

June 5, 2018
Research and Development MSD, Merck, NHS, NICE, keytruda, pharma

UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …

News

Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis

May 11, 2018
Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis

NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …

News
houses-of-parliament-1055056_960_720

UK Ministers call on Vertex to speed up price negotiations

April 23, 2018
Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …

News
roche_glass_building

Tecentriq third time lucky after NICE nod in lung cancer

April 9, 2018
Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq

After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …

News

NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds

April 4, 2018
Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma

UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …

News

NICE turns down Dompe’s eye drops for rare eye condition over price concerns

March 21, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Dompe, NICE, cenegermin, neurotrophic keratitis, pharma, rare disease

NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy …

News

NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy

March 16, 2018
Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma

UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …

News

NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer

February 22, 2018
Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma

NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …

News

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

News

NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma

February 12, 2018
Sales and Marketing Gazyvaro, NHS, NICE, Roche, follicular lymphoma

Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered …

News
The Gateway to Local Adoption Series

Latest content

Sandoz opens biosimilar development centre in Slovenia

June 19, 2026

Codis announces three senior business development appointments

June 18, 2026

US laboratory approval supports launch of lung cancer blood test

June 17, 2026

Study to examine ways of improving diabetes care for younger adults

June 16, 2026

Phase 2 endometriosis trial reaches recruitment milestone

June 15, 2026